An Open-Label Long-Term Safety Study of Serlopitant for the Treatment of Pruritus

Trial Profile

An Open-Label Long-Term Safety Study of Serlopitant for the Treatment of Pruritus

Recruiting
Phase of Trial: Phase III

Latest Information Update: 18 Aug 2018

At a glance

  • Drugs Serlopitant (Primary)
  • Indications Pruritus
  • Focus Adverse reactions; Registrational
  • Sponsors Menlo Therapeutics
  • Most Recent Events

    • 30 May 2018 Status changed from planning to recruiting.
    • 04 Apr 2018 New trial record
    • 28 Mar 2018 According to a Menlo Therapeutics Inc media release, the company expects to start this trial in the second quarter of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top